IN2014MN00635A - - Google Patents

Download PDF

Info

Publication number
IN2014MN00635A
IN2014MN00635A IN635MUN2014A IN2014MN00635A IN 2014MN00635 A IN2014MN00635 A IN 2014MN00635A IN 635MUN2014 A IN635MUN2014 A IN 635MUN2014A IN 2014MN00635 A IN2014MN00635 A IN 2014MN00635A
Authority
IN
India
Prior art keywords
compounds
general formula
oncological
tautomer
solvate
Prior art date
Application number
Other languages
English (en)
Inventor
Germes Grigorievich Chilov
Ilya Yurievich Titov
Original Assignee
Obshchestvo S Ogranichennoy Otvetstvennostyou Fusion Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obshchestvo S Ogranichennoy Otvetstvennostyou Fusion Pharma filed Critical Obshchestvo S Ogranichennoy Otvetstvennostyou Fusion Pharma
Publication of IN2014MN00635A publication Critical patent/IN2014MN00635A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN635MUN2014 2011-06-16 2012-05-29 IN2014MN00635A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2011124304/04A RU2477723C2 (ru) 2011-06-16 2011-06-16 Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
PCT/RU2012/000423 WO2012173521A2 (ru) 2011-06-16 2012-05-29 Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе

Publications (1)

Publication Number Publication Date
IN2014MN00635A true IN2014MN00635A (de) 2015-07-03

Family

ID=47357651

Family Applications (1)

Application Number Title Priority Date Filing Date
IN635MUN2014 IN2014MN00635A (de) 2011-06-16 2012-05-29

Country Status (22)

Country Link
US (1) US9522910B2 (de)
EP (1) EP2743266B8 (de)
AU (1) AU2012269818B2 (de)
CA (1) CA2850137C (de)
CY (1) CY1118513T1 (de)
DK (1) DK2743266T3 (de)
EA (1) EA026704B1 (de)
ES (1) ES2602797T3 (de)
HK (1) HK1195771A1 (de)
HR (1) HRP20161478T1 (de)
HU (1) HUE031837T2 (de)
IL (1) IL232357A (de)
IN (1) IN2014MN00635A (de)
LT (1) LT2743266T (de)
PL (1) PL2743266T3 (de)
PT (1) PT2743266T (de)
RS (1) RS55380B1 (de)
RU (1) RU2477723C2 (de)
SI (1) SI2743266T1 (de)
SM (1) SMT201600398B (de)
UA (1) UA115228C2 (de)
WO (1) WO2012173521A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534335T3 (es) 2010-05-20 2015-04-21 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la Trk cinasa
WO2013170770A1 (zh) * 2012-05-16 2013-11-21 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
US8859553B2 (en) * 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
CN103664787B (zh) * 2012-09-17 2015-09-09 南京圣和药业股份有限公司 炔杂芳环化合物及其应用
CN104341416B (zh) * 2013-07-31 2017-03-29 南京圣和药业股份有限公司 蛋白酪氨酸激酶抑制剂及其应用
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
ES2846153T3 (es) * 2014-03-06 2021-07-28 Univ Southern California Uso de régimen de inanición a corto plazo en combinación con inhibidores de cinasa para potenciar la eficacia y viabilidad de fármacos quimioterápicos tradicionales y revertir efectos secundarios de cinasas en células y tejidos normales
CN106146391A (zh) 2015-04-15 2016-11-23 中国科学院上海药物研究所 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
DK3322706T3 (da) 2015-07-16 2021-02-01 Array Biopharma Inc Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
RU2652992C2 (ru) * 2016-04-18 2018-05-04 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Новая кристаллическая солевая форма 3-(1,2,4-триазоло[4,3-а]пиридин-3-илэтинил)-4-метил-n-(4-((4-метилпиперазин-1-ил)метил)-3-трифторметилфенил)бензамида для медицинского применения
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
RU2664420C1 (ru) * 2017-10-31 2018-08-17 Общество С Ограниченной Ответственностью "Фьюжн Фарма" ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ДОЗИРОВКА И СПОСОБ ЛЕЧЕНИЯ Ph+ ЛЕЙКЕМИЙ
JP7061195B2 (ja) 2018-01-18 2022-04-27 アレイ バイオファーマ インコーポレイテッド RETキナーゼ阻害剤としての置換ピラゾロ[3,4-d]ピリミジン化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
EP3740491A1 (de) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituierte pyrrolo[2,3-d]pyrimidinverbindungen als ret-kinase-inhibitoren
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
BR112021008524A8 (pt) * 2018-11-02 2023-02-07 Merck Sharp & Dohme 2-amino-n-heteroaril-nicotinamidas como inibidores de nav 1.8
WO2022015051A1 (ko) * 2020-07-14 2022-01-20 주식회사 보로노이바이오 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 예방 또는 치료용 약학적 조성물
GB202209210D0 (en) * 2022-06-23 2022-08-10 Univ Strathclyde Cycloaddition reactions
CN116217571A (zh) * 2023-03-28 2023-06-06 上海锐谱医药科技有限公司 一种制备药物砌块1,2,4-三唑并[4,3-a]吡啶-3-胺的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0302173A2 (hu) 2000-09-15 2003-09-29 Vertex Pharmaceuticals Incorporated Protein kináz inhibitorokként alkalmazható pirazolvegyületek
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
US7709520B2 (en) 2000-10-06 2010-05-04 The Texas A&M University System Diindolylmethane and C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
CN1933839A (zh) 2004-01-23 2007-03-21 安进公司 化合物和使用方法
US7745437B2 (en) 2004-06-10 2010-06-29 Irm Llc Compounds and compositions as protein kinase inhibitors
US8158825B2 (en) 2005-06-24 2012-04-17 Merck Sharp & Dohme Corp. Modified malonate derivatives
JP5200939B2 (ja) * 2005-12-23 2013-06-05 アリアド・ファーマシューティカルズ・インコーポレイテッド 二環式ヘテロアリール化合物
EP1989203A2 (de) 2006-02-16 2008-11-12 Millennium Pharmaceuticals, Inc. Alpha-carboline und ihre verwendungen
JP5273037B2 (ja) * 2006-05-08 2013-08-28 アリアド・ファーマシューティカルズ・インコーポレイテッド アセチレン性ヘテロアリール化合物
WO2007145840A2 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7612085B2 (en) 2006-07-11 2009-11-03 Washington University Sigma 2 receptor ligands and therapeutic uses therefor
WO2008077138A1 (en) 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
JP2010531304A (ja) 2007-06-18 2010-09-24 ユニバーシティ オブ ルイビル リサーチ ファウンデーション、インコーポレイテッド 抗悪性腫瘍活性を有するpfkfb3阻害物質ファミリー
US8124768B2 (en) 2008-01-23 2012-02-28 Bristol-Myers Squibb Company 4-pyridinone compounds and their use for cancer
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
US8188109B2 (en) 2009-07-20 2012-05-29 Naxospharma S.R.L. Benzoquinolizinium salt derivatives as anticancer agents
US8242282B2 (en) 2010-05-18 2012-08-14 Taipei Medical University Histone deacetylase inhibitors
RU2011113236A (ru) 2011-04-07 2012-10-20 Общество с ограниченной ответственностью "Фьюжн Фарма" (RU) Новые химические соединения для лечения онкологических заболеваний
WO2013170770A1 (zh) * 2012-05-16 2013-11-21 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
US8859553B2 (en) 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors

Also Published As

Publication number Publication date
CA2850137C (en) 2016-10-25
EA201491356A1 (ru) 2015-01-30
EP2743266A2 (de) 2014-06-18
RS55380B1 (sr) 2017-03-31
ES2602797T3 (es) 2017-02-22
HRP20161478T1 (hr) 2016-12-16
EP2743266B1 (de) 2016-08-17
PT2743266T (pt) 2016-10-14
US20140213592A1 (en) 2014-07-31
CY1118513T1 (el) 2017-07-12
SI2743266T1 (en) 2017-02-28
RU2011124304A (ru) 2012-12-27
EA026704B1 (ru) 2017-05-31
WO2012173521A2 (ru) 2012-12-20
SMT201600398B (it) 2017-01-10
LT2743266T (lt) 2016-12-12
HK1195771A1 (zh) 2014-11-21
DK2743266T3 (en) 2016-12-05
AU2012269818B2 (en) 2016-05-19
IL232357A0 (en) 2014-07-01
UA115228C2 (uk) 2017-10-10
WO2012173521A3 (ru) 2013-03-28
CA2850137A1 (en) 2012-12-20
AU2012269818A1 (en) 2014-06-26
RU2477723C2 (ru) 2013-03-20
EP2743266B8 (de) 2016-09-28
US9522910B2 (en) 2016-12-20
PL2743266T3 (pl) 2017-02-28
HUE031837T2 (en) 2017-08-28
EP2743266A4 (de) 2015-03-11
IL232357A (en) 2017-05-29

Similar Documents

Publication Publication Date Title
IN2014MN00635A (de)
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
TN2011000293A1 (en) Protein kinase inhibitors
TN2014000128A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
AU2012214029A8 (en) Rorgammat inhibitors
MY170656A (en) Kinase inhibitors
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
UA111382C2 (uk) Інгібітори протеїнкінази
EA201171213A1 (ru) Ингибитор р38 мар киназы
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
PL415078A1 (pl) Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
WO2009033033A3 (en) Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
MX2009009786A (es) Inhibidores de la via de hedgehog.
NZ602271A (en) Bicyclic compounds and their uses as dual c-src / jak inhibitors
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
MX342329B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
MX2013011537A (es) Inhibidores de proteina cinasa.
WO2012135697A3 (en) Novel rho kinase inhibitors and methods of use
MY167216A (en) Kinase inhibitors
MX2011012522A (es) Inhibidores de pirazol sustituido de proteina cinasa c-met.
WO2012119006A3 (en) Derivatives of pyrazole-substituted amino-heteroaryl compounds
IN2015MN00045A (de)
PL404138A1 (pl) Pochodne kwasu benzoesowego jako inhibitory receptora IL-15Rα